10 Reasons to Buy Eli Lilly Stock Now

07:39am, Friday, 14'th Jun 2024
The pharmaceutical sector is one that has gone from decades of heavy investment, high growth, and consolidation to a maturing space with a few key players that have more recently provided much more st
Eli Lilly has one obesity drug that's already competing against Wegovy, with more drugs potentially on the way. Novo Nordisk could have a more powerful obesity drug than Wegovy waiting in the wings.
Far from being a source of concern, the U.S. stock market's extremely low volatility is something to celebrate. The CBOE Volatility Index VIX, or VIX, which is a measure of the S&P 500's SPX expected
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

3 Stocks to Buy as Ozempic Surges in Popularity

06:15am, Thursday, 13'th Jun 2024
Ozempic and Wegovy (semaglutide for diabetes and weight loss, respectively) are popular weight-loss drugs that have taken the world by storm. Indeed, the craze is showing no signs of slowing down as m
You won't want to miss out on the stock Warren Buffett has been scooping up. A healthcare leader is poised to capture the lion's share of a potential $130 billion weight loss market.
It remains a tale of two markets. Some stocks have wind in their sails and are soaring to all-time highs.
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
Artificial intelligence is forecast to drive an innovation bonanza in healthcare. This innovation boom is expected to increase the human lifespan dramatically.
Eli Lilly's revenue has taken off thanks to two of its drugs that doctors prescribe for weight loss. The company also has a full portfolio of other products, and some increased revenue in the double d
'Mad Money' host Jim Cramer breaks down Eli Lilly's success in pharmaceutical drugs and where the stock can go from here.
'Mad Money' host Jim Cramer breaks down Eli Lilly's success in pharmaceutical drugs and where the stock can go from here.
Eli Lilly (LLY) is one step closer to getting its new Alzheimer's treatment approved by the Food and Drug Administration (FDA) after a panel voted to recommend its use. BMO Capital Markets Managing Di
Eli Lilly and Company has gained approval on yet another prospective blockbuster drug, Donanemab, the second FDA-approved Alzheimer's treatment on the market. It is too soon to know what kind of impac
BofA Securities analyst Geoff Meacham reiterated the Buy rating on Eli Lilly And Company LLY, with a price forecast of $1,000.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE